复宏汉霖续涨10.8% 有望“五连涨” 就HLX15与Dr.Reddy’s订立许可协议+H药汉斯状®于欧盟获批上市

格隆汇
07 Feb

复宏汉霖(2696.HK)盘中涨超10.8%,报20.5港元,有望实现“五连涨”。该股近五个交易日累计上涨超20%。消息面上,复宏汉霖公告,公司于2025年2月6日与Dr. Reddy’s Laboratories SA订立一份许可协议,据此,公司向Dr.Reddy’s授出一项许可,供其于美国及约定的欧洲地区(包括英国、瑞士等42个欧洲国家)内及领域内开发、生产和商业化HLX15(重组抗CD38...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10